Skip to content
Screener

Xenon Pharmaceuticals XENE Q4 2025 Annual earnings

Reported February 26, 2026 · After market close

Revenue-
EPS-$1.31Miss by $0.11
EPS estimate-$1.20

Next report

Nov 2, 2026 (in a month)
Revenue estimate$1.3M
EPS estimate-$1.17

Financials

Q4 2025

Income statement

See full
Revenue-—
Operating income-$109.8M-41.7%
Net income-$105.3M-60.3%
EPS (diluted)-$1.31-56.0%

Balance sheet

See full
Cash & equivalents$199.2M+39.6%
Total debt$7.9M-11.9%
Total equity$581.8M-22.9%
Total assets$633.2M-20.7%

Cash flow

See full
Operating cash flow-$81.5M-49.8%
CapEx$318.0K-59.4%
Free cash flow-$81.8M-48.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$3.46B+15.9%
Enterprise value$3.27B+14.6%
P/S461.8×—

Profitability

See full
Operating margin-4,974.3%—
Net margin-4,612.1%—
FCF margin-3,732.2%—

Returns & leverage

See full
Return on equity-51.8%+314pp
Debt / equity0×0.0×
Current ratio13.4×-4.4×

FAQ

When did Xenon Pharmaceuticals report Q4 2025 earnings?
Xenon Pharmaceuticals (XENE) reported Q4 2025 earnings on February 26, 2026 after market close.
What were Xenon Pharmaceuticals's Q4 2025 revenue and EPS?
Xenon Pharmaceuticals reported revenue of - and eps of $-1.31 for Q4 2025.
Did Xenon Pharmaceuticals beat estimates in Q4 2025?
EPS missed the consensus estimate of $-1.20 by $0.11.
How did Xenon Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 56.0% from $-0.84.
Where can I find Xenon Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-076530) and the 10-K periodic report (0001193125-26-076650) directly on SEC EDGAR. The filing index links above go to sec.gov.